Literature DB >> 35704154

Liver biopsy technique in the era of genomic cancer therapies: a single-center retrospective analysis.

Yusuke Ozeki1, Naoya Kanogawa1, Sadahisa Ogasawara2,3, Keita Ogawa1, Takamasa Ishino1, Miyuki Nakagawa1, Kisako Fujiwara1, Hidemi Unozawa1, Terunao Iwanaga1, Takafumi Sakuma1, Naoto Fujita1, Ryuta Kojima1, Hiroaki Kanzaki1, Keisuke Koroki1, Kazufumi Kobayashi1,4, Masato Nakamura1, Soichiro Kiyono1, Takayuki Kondo1, Tomoko Saito1, Ryo Nakagawa1, Eiichiro Suzuki1, Yoshihiko Ooka1, Shingo Nakamoto1, Ryosuke Muroyama1, Akinobu Tawada1,5, Tetsuhiro Chiba1, Makoto Arai1,5, Jun Kato1, Jun-Ichiro Ikeda6, Yuichi Takiguchi5, Naoya Kato1.   

Abstract

BACKGROUND: With the evolution of personalized medicine in the field of oncology, which includes optimal treatment selection using next-generation sequencing-based companion diagnostic systems and tumor-agnostic treatments according to common biomarkers, a liver tumor biopsy technique that can obtain a sufficient specimen volume must be established. The current study aimed to evaluate the safety and availability of a liver tumor biopsy technique with multiple puncture sites made using a coaxial introducer needle and embolization with gelatin sponge particles.
METHODS: Patients with primary or metastatic liver cancer who underwent liver tumor biopsies with puncture tract embolization using gelatin sponge (Spongel®) from October 2019 to September 2020 were included in the study. The complication and diagnostic rates were evaluated, and whether the specimen volume was sufficient for Foundation® CDx was investigated.
RESULTS: In total, 96 patients were enrolled in this analysis. The median total number of puncture times per patient was 3 (range 1-8). The pathological diagnostic rate was 79.2%. Using the FoundationOne® CDx, specimens with a sufficient volume required for genomic medicine were collected in 84.9% of patients. The incidence rate of bleeding was 4.2% (n = 4), and only one patient presented with major bleeding requiring transfusion.
CONCLUSIONS: Liver biopsy with puncture tract embolization using a gelatin sponge may be safe and effective for collecting specimens with a volume sufficient for modern cancer treatments.
© 2022. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.

Entities:  

Keywords:  Complication; Diagnostic rate; Gelatin sponge; Genomic medicine; Liver biopsy

Mesh:

Substances:

Year:  2022        PMID: 35704154     DOI: 10.1007/s10147-022-02195-9

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.850


  41 in total

1.  Nivolumab in previously untreated melanoma without BRAF mutation.

Authors:  Caroline Robert; Georgina V Long; Benjamin Brady; Caroline Dutriaux; Michele Maio; Laurent Mortier; Jessica C Hassel; Piotr Rutkowski; Catriona McNeil; Ewa Kalinka-Warzocha; Kerry J Savage; Micaela M Hernberg; Celeste Lebbé; Julie Charles; Catalin Mihalcioiu; Vanna Chiarion-Sileni; Cornelia Mauch; Francesco Cognetti; Ana Arance; Henrik Schmidt; Dirk Schadendorf; Helen Gogas; Lotta Lundgren-Eriksson; Christine Horak; Brian Sharkey; Ian M Waxman; Victoria Atkinson; Paolo A Ascierto
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

2.  Liver biopsy.

Authors:  Don C Rockey; Stephen H Caldwell; Zachary D Goodman; Rendon C Nelson; Alastair D Smith
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

3.  Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.

Authors:  Mark G Kris; Bruce E Johnson; Lynne D Berry; David J Kwiatkowski; A John Iafrate; Ignacio I Wistuba; Marileila Varella-Garcia; Wilbur A Franklin; Samuel L Aronson; Pei-Fang Su; Yu Shyr; D Ross Camidge; Lecia V Sequist; Bonnie S Glisson; Fadlo R Khuri; Edward B Garon; William Pao; Charles Rudin; Joan Schiller; Eric B Haura; Mark Socinski; Keisuke Shirai; Heidi Chen; Giuseppe Giaccone; Marc Ladanyi; Kelly Kugler; John D Minna; Paul A Bunn
Journal:  JAMA       Date:  2014-05-21       Impact factor: 56.272

4.  First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication.

Authors:  Steven Lemery; Patricia Keegan; Richard Pazdur
Journal:  N Engl J Med       Date:  2017-10-12       Impact factor: 91.245

5.  Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study.

Authors:  Kaname Nosaki; Miyako Satouchi; Takayasu Kurata; Tatsuya Yoshida; Isamu Okamoto; Nobuyuki Katakami; Fumio Imamura; Kaoru Tanaka; Yuki Yamane; Nobuyuki Yamamoto; Terufumi Kato; Katsuyuki Kiura; Hideo Saka; Hiroshige Yoshioka; Kana Watanabe; Keiko Mizuno; Takashi Seto
Journal:  Lung Cancer       Date:  2016-07-06       Impact factor: 5.705

6.  Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.

Authors:  Nadeem Riaz; Jonathan J Havel; Vladimir Makarov; Alexis Desrichard; Walter J Urba; Jennifer S Sims; F Stephen Hodi; Salvador Martín-Algarra; Rajarsi Mandal; William H Sharfman; Shailender Bhatia; Wen-Jen Hwu; Thomas F Gajewski; Craig L Slingluff; Diego Chowell; Sviatoslav M Kendall; Han Chang; Rachna Shah; Fengshen Kuo; Luc G T Morris; John-William Sidhom; Jonathan P Schneck; Christine E Horak; Nils Weinhold; Timothy A Chan
Journal:  Cell       Date:  2017-10-12       Impact factor: 41.582

7.  Rebiopsy of Histological Samples in Pretreated Non-small Cell Lung Cancer: Comparison Among Rebiopsy Procedures.

Authors:  Akito Hata; Nobuyuki Katakami; Shigeki Nanjo; Chiyuki Okuda; Reiko Kaji; Yukihiro Imai
Journal:  In Vivo       Date:  2017 May-Jun       Impact factor: 2.155

Review 8.  Combination Immunotherapy in Non-small Cell Lung Cancer.

Authors:  Melina E Marmarelis; Charu Aggarwal
Journal:  Curr Oncol Rep       Date:  2018-05-08       Impact factor: 5.075

9.  Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.

Authors:  Tony S K Mok; Yi-Long Wu; Iveta Kudaba; Dariusz M Kowalski; Byoung Chul Cho; Hande Z Turna; Gilberto Castro; Vichien Srimuninnimit; Konstantin K Laktionov; Igor Bondarenko; Kaoru Kubota; Gregory M Lubiniecki; Jin Zhang; Debra Kush; Gilberto Lopes
Journal:  Lancet       Date:  2019-04-04       Impact factor: 79.321

10.  Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer.

Authors:  Beth O Van Emburgh; Sabrina Arena; Giulia Siravegna; Luca Lazzari; Giovanni Crisafulli; Giorgio Corti; Benedetta Mussolin; Federica Baldi; Michela Buscarino; Alice Bartolini; Emanuele Valtorta; Joana Vidal; Beatriz Bellosillo; Giovanni Germano; Filippo Pietrantonio; Agostino Ponzetti; Joan Albanell; Salvatore Siena; Andrea Sartore-Bianchi; Federica Di Nicolantonio; Clara Montagut; Alberto Bardelli
Journal:  Nat Commun       Date:  2016-12-08       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.